Subsequent investigation revealed its ability to drive robust EGFR hyperactivation by enhancing autocrine amphiregulin release from HNSCC cells, thus hyperactivating EGFR signaling61, and rendering hypersensitivity to an EGFR kinase inhibitor, erlotinib. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.